Islatravir/lenacapavir vs Lenacapavir (Yeztugo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV capsid · full HIV pipeline

Islatravir/lenacapavir

Developed by Gilead Sciences and partners

Phase 3 in HIVsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Lenacapavir (Yeztugo)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Reliable signal

NCT04994509 · Phase 3 · active, not recruiting

This is a very large randomized, double-blind trial with active-control arms and a hard primary endpoint, HIV-1 infection. Lenacapavir's HIV incidence was far below the background rate and met the prespecified superiority tests. The primary comparison is against a background rate estimated from screened participants, not directly against the control arms.

Next expected readout: March 2027 · NCT07210125 (registry estimate)

Reported efficacy

Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY) (Incidence Phase Screening Visit (Day 1)); Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set) (Up to 149 weeks): HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025). (met)

Result source: NCT04925752

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIslatravir/​lenacapavirLenacapavir (Yeztugo)
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT06630286—Trial running · NCT04925752
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06630286—Trial running · NCT04925752
CD4 count, change (week 48)—Trial running · NCT06630286—Trial running · NCT04925752

HIV-1 RNA below 50 copies/mL (week 48)

Islatravir/​lenacapavir
—Trial running · NCT06630286
Lenacapavir (Yeztugo)
—Trial running · NCT04925752

HIV-1 RNA 50 copies/mL or more (week 48)

Islatravir/​lenacapavir
—Trial running · NCT06630286
Lenacapavir (Yeztugo)
—Trial running · NCT04925752

CD4 count, change (week 48)

Islatravir/​lenacapavir
—Trial running · NCT06630286
Lenacapavir (Yeztugo)
—Trial running · NCT04925752
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Islatravir/lenacapavir: no structured comparison results are available for HIV.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Islatravir/lenacapavir: 0 of 4 rows · Lenacapavir (Yeztugo): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLenacapavir (Yeztugo)
Dropout rate
11.5%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
94.4%
NCT04925752 · Phase 3 · combination · HIV · phase 3
Discontinued due to AEs
0.1%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
0.2%
NCT04925752 · Phase 3 · combination · HIV · phase 3
Serious AEs
3.8%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
3.3%
NCT04925752 · Phase 3 · combination · HIV · phase 3
Most frequent reported AEs
injection site nodule 66.1%
injection site pain 34.2%
genitourinary chlamydia infection 16.4%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
injection site nodule 63.4%
injection site pain 56.4%
injection site erythema 17.3%
NCT04925752 · Phase 3 · combination · HIV · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lenacapavir (Yeztugo)

HIV-1 Incidence Per 100 PY 0 vs 2.018 F/TAF per 100 person year @ 52wk
event count · per 100 person year
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
0 vs 2.018 F/TAF per 100 person year @ 52wk
NCT04994509 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Per 100 PY 0 per 100 person year @ 52wk
event count · per 100 person year
No placebo or comparator arm
NCT04994509 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Rate Per 100 PY 0.103 per 100 person year @ 149wk
event rate · per 100 person year
No placebo or comparator arm
NCT04925752 · Phase 3 · combination · HIV · phase 3
show 1 more result
0.125 per 100 person year @ 149wk
NCT04925752 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Rate Per 100 PY 0.103 vs 0.931 F/TDF per 100 person year @ 149wk
event rate · per 100 person year
NCT04925752 · Phase 3 · combination · HIV · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Islatravir/lenacapavir's landscape · Lenacapavir (Yeztugo)'s landscape